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Insulin resistance has been hypothesized to act as a common 
pathogenic defect for type 2 diabetes and coronary artery disease, 
although the molecular mechanisms explaining its effects are still 
unclear (1–3). Insulin resistance can bring about the development 
of the inflammatory state, leading to atherosclerosis by altering 
lipid metabolism and adiposity (4). Conversely, activation of the 
innate immune system may be linked to insulin resistance, as 
observed in epidemiological studies reporting subclinical inflam-
mation in insulin-resistant states (5, 6). Another, yet unexplored, 
possibility is that interaction between 2 or more genes can simulta-
neously induce insulin resistance and inflammatory state in both 
insulin target tissues (muscle, fat, liver) and in vasculature.
Heterozygosity for a null insulin receptor (Insr+/–) allele is associ-
ated with a variable pattern of insulin resistance in mice (7–9). The 
variability of the metabolic phenotypes due to the Insr mutation 
results partly from environmental factors and partly from genetic 
modifiers that have been primarily mapped (8–11). Insr+/– mice 
have been helpful in the study of different aspects of type 2 dia-
betes pathogenesis. In fact, interaction of Insr haploinsufficiency 
with insulin receptor substrate 1 (Irs1) ablation or loss of Foxo1 func-
tion recapitulates the role of pancreatic β cell, skeletal muscle, and 
liver function in controlling glucose homeostasis (9–11). How-
ever, the interaction between these genes has not hitherto offered 
insights into the links between diabetes and atherosclerosis.
Here, we show that Insr+/– mice that are diabetic have a defect in 
tissue inhibitor of metalloproteinase 3 (Timp3) expression. Timp3 
is unique compared with the other members of the TIMP family in 
its ability to block activation of both TNF-α convertase and classical 
metalloproteinases such as MMP-2 and MMP-9 (12, 13). We show in 
vivo that reduced Timp3 expression results in uncontrolled TNF-α– 
converting enzyme (TACE) protease activity, therefore increasing the 
levels of circulating soluble TNF-α. The unchecked inflammatory 
state caused by Timp3 deficiency interacts with Insr haploinsufficien-
cy, leading to glucose intolerance as well as vascular inflammation.
Furthermore, our study points out that diabetes and atheroscle-
rosis could be determined by common pathways, which are ame-
nable to therapeutic modulation.
Results
To complement a previous study showing a genetic basis for dia-
betes in Insr+/– mice (8), we used the same type of mice to perform 
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a differential display on mRNA extracted from skeletal muscle. We 
identified 11 gene products differentially expressed in Insr+/– diabetic 
compared with Insr+/– normoglycemic mice (Table 1). In Insr+/– dia-
betic mice, we found a marked decrease in the expression of Timp3, 
an endogenous and selective inhibitor of MMPs and sheddases such 
as ADAM-17/TACE (12, 13). Although we were unable to identify 
a primary defect in the Timp3 gene that might explain its reduced 
expression, we reasoned that its deficiency may contribute to impair-
ing glucose homeostasis in Insr+/– mice, given Timp3’s pivotal role in 
controlling activation of the innate immune system (14).
Identification of Timp3 as a common element for glucose intolerance and 
vascular inflammation. To establish the role of Timp3 in diabetes, 
we used male Insr+/– and their male WT littermates on a mixed 
C57BL6/SV129J background. Thus, we divided Insr+/– mice into 
normoglycemic (Insr+/–N) and diabetic (Insr+/–D, markedly hyper-
glycemic and hyperinsulinemic) groups (Table 2). Since Timp3 
deficiency may result in increased levels of circulating and tissue 
soluble TNF-α, we analyzed TNF-α levels in serum and relevant 
tissues for insulin action. Results showed that TNF-α is detectable 
only in serum and skeletal muscle of Insr+/–D mice and not in WT 
and Insr+/–N mice (Figure 1A).
We then sought to confirm whether a defect in Timp3 expres-
sion and activity in the skeletal muscle of these mice is associat-
ed with diabetes. Quantitative real-time PCR, Western blot, and 
reverse zymography assays confirmed a significant reduction in 
Timp3 mRNA (65% and 75%), protein (78% and 70%), and activity 
(50% and 45%) in skeletal muscle of Insr+/–D mice compared with 
WT and Insr+/–N littermates, respectively (Figure 1, B–D). Reduc-
tion of Timp3 expression and activity also correlated with a signifi-
cant decrease in the pro–TNF-α form and significant increase in 
soluble TNF-α in skeletal muscle homogenates from Insr+/–D mice 
(Figure 1E). We hypothesized that decreased proTNF-α in Insr+/–D 
mice was due to increased TACE activity. To verify specificity of 
TACE shedding, we measured levels of proTNF-α, pro–IL-6R, and 
pro-CD40 in isolated muscle membranes (15, 16). All membrane-
bound TACE substrates were decreased in Insr+/–D mice (Figure 1F). 
Similarly, TACE activity measured by a fluorimetric assay was 
increased in total skeletal muscle homogenates from Insr+/–D mice 
(Figure 1G). Addition to muscle extracts of recombinant Timp3 
reduced this enzymatic activity, while recombinant Timp2, which 
is unable to block TACE, did not yield the same result (Figure 1G). 
Likewise, adding the MMP-specific inhib-
itor BMS-275291 did not modify the 
increased enzymatic activity in muscle 
from Insr+/–D mice (Figure 1G). This spe-
cific response to Timp3 compared with 
Timp2 and BMS-275291 is suggestive of 
TACE activity (14, 17). Next, we hypothe-
sized that increased availability of TNF-α 
could impair insulin action by interfering 
with IRS-1 activation. TNF-α signaling 
activates JNK-1, which phosphorylates 
IRS-1 on Ser307. This serine phosphory-
lation reduces the ability of IRS-1 to be 
tyrosine phosphorylated by the Insr, a 
step required for insulin metabolic action 
such as glucose transport (18). We found 
that IRS-1 phosphorylation on Ser307 
was increased in skeletal muscle from ran-
domly fed Insr+/–D mice (Figure 1H).
We then investigated the presence of vascular inflammation asso-
ciated with diabetes. Similar to what we found in muscle, Timp3 was 
reduced in aortas from Insr+/–D mice at the level of mRNA (50%), 
protein (50%), and activity (50%) (Figure 2, A–C) compared with both 
Insr+/–N and WT mice. To verify the presence of vascular inflamma-
tion, we analyzed levels of MMP-2 and MMP-9. We found increases 
in gelatinolytic activity in bands corresponding to pro–MMP-9 and 
pro–MMP-2 in tissue from Insr+/–D aortas compared with WT and 
Insr+/–N aortas (Figure 2D). Since TIMPs would have no inhibitory 
effect in the gel, as they separate from the MMPs during electro-
phoresis, the increase in gelatinase activity was probably due to an 
increase in MMP expression consequent to the excess of TNF-α.
Next, we analyzed markers of vascular inflammation and athero-
sclerosis such as monocyte chemotactic protein 1 (MCP-1) (19) and 
VCAM-1 (20). By Western blotting, Insr+/–D animals displayed a 
3.2-fold and 3.4-fold increase in vascular expression of MCP-1 and 
VCAM-1, respectively (Figure 2, E and F) compared with Insr+/–N 
and WT mice. We next studied vascular levels of cyclooxygenase-2 
(cox-2) and ox-LDL receptor–1 (LOX-1), because these molecules 
are associated with proinflammatory mechanisms and oxidant 
stress in atherosclerosis (21, 22). Levels of cox-2 and LOX-1 anti-
gens in aortas were enhanced 3.3-fold and 4.4-fold, respectively in 
Insr+/–D mice (Figure 2, G and H).
Interaction between Insr haploinsufficiency and reduced Timp3 expres-
sion in the muscle as a cause of hyperglycemia. We hypothesized that 
the reduction in Timp3 expression in adult mice carrying the Insr 
mutation but normoglycemic, as the Insr+/–N, should result in an 
increase in soluble TNF-α and consequently an impairment in 
insulin sensitivity, similar to what was observed in Insr+/–D mice. To 
Table 1
Summary of differential display data
Clone no. Expression Match Accession no.
1 Insr+/–N > Insr+/–D TIMP-3 gi|984750
2 Insr+/–N > Insr+/–D Cytochrome c oxidase VIIB gi|3234214
3 Insr+/–N > Insr+/–D Mouse mitochondrial genome gi|13838
4 Insr+/–D > Insr+/–N Human nebulin mRNA gi|1205987
5 Insr+/–N > Insr+/–D Mouse CaM kinase II mRNA gi|50275
6 Insr+/–D > Insr+/–N Mitochondrial stress-70 protein gi|460726
7 Insr+/–D > Insr+/–N Human titin mRNA gi|1017426
8 Insr+/–D > Insr+/–N Mouse mRNA for Melk gi|1177538
9 Insr+/–D > Insr+/–N Mouse mitochondrial genome gi|13838
10 Insr+/–D > Insr+/–N Alu 2 region-T cell gi|1245821
11 Insr+/–N > Insr+/–D Human calmodulin mRNA gi|179809
The best sequence match derived from a BLASTn search of the non-redundant and expressed 
sequence tag (EST) GenBank database is given, along with the GenBank identifier. >, increased 
compared with.
Table 2
Metabolic data for Insr+/–D, Insr+/–N, and WT littermates on a 
C57BL6/SV129J mixed background
Group n Glucose (mg/dl) Insulin (ng/ml)
WT 60 97 ± 4A 3.7 ± 0.7A
Insr+/–D 24 311 ± 36 21.8 ± 0.8
Insr+/–N 75 102 ± 6A 4.8 ± 1.4A
Values are statistically significant compared with Insr+/–D (AP < 0.01 by 
1-way ANOVA).
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knock down Timp3 levels in the skeletal muscle of Insr+/–N adult 
mice, we used small interfering RNA (siRNA). We tested in 3T3L1 
cells 5 different siRNAs for their ability to knock down	Timp3, 
obtaining an 80% decrease in Timp3 expression with insert 3 (data 
not shown). We used this construct for in vivo Timp3 knockdown 
(KD). We found that reduction in Timp3 mRNA and protein was 
Figure 1
Timp3 expression and activity in skeletal muscle of Insr+/–mice. (A) Quantification of TNF-α in Insr+/–D, Insr+/–N, and WT littermates. (B) Real-
time RT-PCR analysis of Timp3 mRNA expression in Insr+/–D, Insr+/–N, and WT mice. **P < 0.01; †P < 0.001 by 1-way ANOVA. (C) Western blot 
analysis of Timp3 protein expression in Insr+/–D, Insr+/–N, and WT mice (equal loading was confirmed by silver staining). **P < 0.01 by 1-way 
ANOVA. (D) Comparison of Timp3 activity, measured by reverse zymography in Insr+/–D, Insr+/–N, and WT mice (equal loading was confirmed 
by silver staining). *P < 0.05 by 1-way ANOVA. (E) Pro–TNF-α to TNF-α conversion in Insr+/–D (lanes 3 and 4), Insr+/–N (lanes 5 and 6), and WT 
(lanes 1 and 2) mice. *P < 0.05 by 1-way ANOVA. (F) Shedding of ProTNF-α, pro–IL-6R, and pro-CD40 in Insr+/–D, Insr+/–N, and WT mice. Gel 
loading was normalized by anti–IGF-1R. (G) TACE activity measured by a fluorimetric assay in Insr+/–D, Insr+/–N, and WT mice in the presence 
or absence of recombinant Timp3 (rTimp-3) (100 mM), recombinant Timp2 (rTimp-2) (100 mM), and specific MMP inhibitor BMS-275291 (1 µM). 
**P < 0.01 versus WT; #P < 0.01 versus Insr+/–D by 1-way ANOVA. (H) IRS-1 phosphorylation on Ser307 in Insr+/–D, Insr+/–N, and WT. *P < 0.05 
by 1-way ANOVA. Data from 3 separate experiments are summarized in the bar graphs and expressed as mean ± SD.
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significant 24 hours after injection and stable until 72 hours 
(Figure 3, A and B). To confirm the specificity of the Timp3 siRNA, 
we assessed Timp2 protein levels that were unaffected by Timp3 
siRNA (Figure 3C). Once the time course for Timp3 KD was estab-
lished, we injected WT mice (WT/Timp3KD), Insr+/–N mice (Insr+/–N/ 
Timp3KD), and Veh-Insr+/– mice (injected with plasmid only) in 
all 4 legs. In parallel to the observed changes in Timp3 expression, 
blood glucose levels rose significantly 24 hours after the injec-
tion and remained higher until 72 hours in Insr+/–N/Timp3KD 
but not in WT/Timp3KD and Veh-Insr+/– mice (Figure 3D). 
To verify that the increase in glucose levels was consequent to 
Timp3 KD, we performed glucose tolerance tests in Insr+/–N mice 
before and after the injection of either an in vivo functional siRNA 
specific for cyclophilin A, a gene unrelated to Timp3 (Figure 3E), the 
delivery solution, or the empty pRNA-U6.1/neo vector. In all cases, 
injection had no effect on glucose tolerance (Figure 3, F–H). Inter-
estingly, in Insr+/– mice TNF-α levels were found to be increased 
only by Timp3 KD in skeletal muscle and unaffected by injections 
of unrelated siRNA, delivery solution, or vector (Figure 3I).
Glucose tolerance tests demonstrated that Insr+/–N/Timp3KD 
mice were significantly hyperglycemic and hyperinsulinemic com-
pared with WT, Insr+/–N, WT/Timp3KD, and Insr+/–N/Veh mice 
(Figure 4, A and B). To verify that Insr+/–N/Timp3KD are insulin 
resistant in the skeletal muscle, the primary site of Insr/Timp3 
interaction, and in the liver and white adipose tissue (WAT), we 
used glucose tolerance tests incorporating the tracer [3H]2-deoxy-
glucose (23). By this assay, we determined glucose uptake at 120 
minutes after glucose loading in muscle and WATs as well as glu-
cose incorporation into glycogen in liver. Glucose uptake was mark-
edly impaired in muscle from Insr+/–N/Timp3KD compared with 
WT, WT/Timp3KD, and Insr+/–N mice. Notably, glucose uptake 
in WAT and glucose incorporation in liver glycogen were mild 
but significantly reduced in Insr+/–N/Timp3KD mice (Figure 4, 
C–E), confirming our hypothesis.
Figure 2
Decreased Timp3 activity and increased inflammation in aortas of Insr+/–D mice. (A) Real-time RT-PCR analysis of Timp3 mRNA expression in 
Insr+/–D, Insr+/–N, and WT mice. †P < 0.001 by 1-way ANOVA. (B) Western blot analysis of Timp3 protein expression in Insr+/–D, Insr+/–N, and 
WT mice (equal loading was confirmed by silver staining). **P < 0.01 by 1-way ANOVA. (C) Comparison of Timp3 activity, measured by reverse 
zymography in Insr+/–D, Insr+/–N, and WT mice (equal loading was confirmed by silver staining). *P < 0.05 by 1-way ANOVA. (D) MMP measured 
by zymography in Insr+/–D, Insr+/–N, and WT mice. Mouse MMP-9 and human MMP-2/9 were used as standards. **P < 0.01, *P < 0.05 by 1-way 
ANOVA. Analysis by Western blotting of inflammatory markers, MCP-1 (E), VCAM-1 (F), cox-2 (G), LOX-1 (H), and tubulin as control in Insr+/–D, 
Insr+/–N, and WT mice. **P < 0.01, †P < 0.001 by 1-way ANOVA. Data from 3 separate experiments are summarized in the bar graphs and 
expressed as mean ± SD.
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To gain insights into the molecular mechanism by which Timp3 
reduction alters glucose homeostasis, we performed signaling stud-
ies in tissues relevant for insulin action and glucose metabolism. In 
skeletal muscle, Timp3 KD resulted in increased phosphorylation 
of JNK-1/2 and of IRS-1 at Ser307, both signs of increased TNF-α 
activity, only in Insr+/–N/Timp3KD compared to WT, WT/Timp3KD, 
Insr+/–N and WT mice (Figure 5A). Upon insulin injection, Insr β 
subunit and IRS-1 tyrosine phosphorylation, phosphotyrosine-
associated PI3K activity and Akt phosphorylation on Ser473 were 
significantly decreased in Insr+/–N/Timp3KD compared with WT, 
WT/Timp3KD and Insr+/–N mice (Figure 5, B–E). Next, we analyzed 
insulin action in liver and WAT of mice upon insulin challenge. In 
liver we found decreased phosphotyrosine-associated PI3K activity 
and Akt phosphorylation on Ser473 in Insr+/–N/Timp3KD (Figure 5, 
F and G). Impairment of the metabolic branch of insulin signaling 
in Insr+/–N/Timp3KD resulted in decreased phosphorylation of gly-
cogen synthase kinase 3β on Ser9 (Figure 5H), accounting for the 
observed reduction in glucose incorporation into glycogen. In WAT 
from Insr+/–N/Timp3KD mice, we observed reduced phosphotyro-
sine-associated PI3K activity (Figure 5I).
These results suggested that Timp3 plays a role in altering glu-
cose homeostasis in vivo when interacting with defects in insulin 
action such as those due to Insr haploinsufficiency. Whether the 
Timp3/TACE dyad plays a role in regulation of glucose homeosta-
sis is at present unclear. In fact, unrestrained TACE activity has been 
hypothesized to increase TNF-α expression in obesity (24). However, 
adipose tissue–restricted TNF-α action alone is insufficient to cause 
insulin resistance (25). To directly address these issues, we investigat-
ed glucose homeostasis in mice obtained from breeding Insr+/– with 
Timp3+/– and Tace+/– mice, all on a C57BL/129SV mixed background 
Figure 3
Effect of Timp3 KD in skeletal muscle. siRNA-mediated inhibition of Timp3 mRNA (A) and protein (B) expression in mice injected with insert 
3 containing vector at 8 hours, 24 hours, and 72 hours after injection. I, muscle injected with insert; C, contralateral muscle injected only with 
vehicle. Data from 3 separate experiments are summarized in the bar graphs and expressed as mean ± SD. (C) Effect of Timp3 KD on Timp2 
protein levels. (D) Fed glucose levels in Insr+/–N/Timp3KD mice (open circles), WT/Timp3KD (filled squares), and Insr+/–N mice injected with 
vehicle (Insr+/–N/Veh; open diamonds). Data are expressed as mean ± SD (n = 6 per group). *P < 0.05, **P < 0.01. (E) Effect of cyclophilin A 
siRNA on cyclophilin A mRNA and protein level in Insr+/–N mice. (F–H) Intraperitoneal glucose tolerance tests before (Pre) and after (Post) 
injection of cyclophilin A (G), delivery solution (F), or empty plasmid (H) (n = 3 per group). (I) TNF-α levels in Insr+/–N mice injected with siRNA 
reagents and in Insr+/–N/cyclophilin A KD and Insr+/–N/Timp3KD mice. Data are expressed as mean ± SD (n = 3–6 per group).
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(14, 26). At 3 months Insr+/–Timp3+/– mice were hyperinsulinemic and 
hyperglycemic in the fed state compared with Insr+/–Tace+/–, Insr+/–, 
Timp3+/–, Tace+/–, and WT littermates (Figure 6, A–D). Intraperitoneal 
glucose and insulin tolerance tests showed a mild defect in glucose 
tolerance at 3 months in Insr+/–Timp3+/– mice compared with the 
other genotypes (Figure 6, E and F). At 6–8 months old, in both the 
fasted and the fed state, Insr+/–Timp3+/– mice were significantly hyper-
glycemic and hyperinsulinemic compared with the other genotypes 
(Figure 7, A–D). Intraperitoneal glucose tolerance tests corroborated 
that Insr+/–Timp3+/– mice were significantly hyperglycemic and hyper-
insulinemic (Figure 7, E and F). Intraperitoneal insulin tolerance 
tests confirmed that Insr+/–Timp3+/– mice were insulin resistant com-
pared with the other genotypes (Figure 7G). Moreover, we observed 
that Tace haploinsufficiency is associated with mildly increased insu-
lin sensitivity compared with WT mice (Figure 7, E–G). TNF-α levels 
increased in both serum and skeletal muscle of Insr+/–Timp3+/– mice 
compared with the other genotypes (Figure 7H).
Reconstitution of Timp3 activity by inhibition of TACE/MMP-2/9 activi-
ty improves diabetes and vascular inflammation in Insr+/–D mice. Because 
we observed increased conversion of proTNF-α to TNF-α in the 
skeletal muscle of Insr+/–D mice, we hypothesized that circulating 
TNF-α levels could be affected as a consequence of reduced inhibi-
tion of TACE by Timp3 both in skeletal muscle and vasculature. 
Serum TNF-α levels were increased in Insr+/–D mice compared 
with WT and Insr+/–N mice (Figure 1A). Thus, we treated Insr+/–D 
mice (Figure 8A) with single injections of anti–TNF-α neutralizing 
antibody, observing a significant reduction in fed glucose levels 24 
hours after treatment. Since circulating TNF-α reflects the degree 
of TACE activity, we considered, as an alternative approach, inhib-
iting the function of TACE in vivo. We treated WT, Insr+/–N, and 
Insr+/–D mice with TNF-α protease inhibitor 1 (TAPI-1), a synthet-
ic TACE/MMP inhibitor that is known to modulate proTNF-α 
to TNF-α conversion and also to inhibit MMP-2 and MMP-9, 
thus mimicking both the 2 main Timp3 activities (12, 13, 26). We 
observed that treatment with TAPI-1 reduced fed glucose levels 
to normal values within 24 hours of the first injection in Insr+/–D 
mice (Figure 8B). Treatment was continued with daily administra-
tion for 1 week. Twenty-four hours after withdrawal of the drug, 
fed blood glucose levels began to rise (data not shown). Two weeks 
after discontinuing TAPI-1, blood glucose levels in Insr+/–D mice 
were comparable to pretreatment levels (Figure 8B). Similarly, fed 
insulinemia decreased in Insr+/–D mice during TAPI-1 treatment, 
returning to pretreatment levels within 2 weeks of discontinuing 
TAPI-1 (Figure 8C). Interestingly, fed insulin levels were modestly 
reduced after TAPI-1 in Insr+/–N mice (Figure 8C).
To prove that positive effects of TACE inhibition are paralleled by 
reduction in circulating TNF-α in Insr+/–D mice, we measured TNF-α 
levels before and after 1 week of treatment in WT and Insr+/–D 
mice. Interestingly, TAPI-1 reduced TNF-α levels (Figure 8D). 
By contrast, TAPI-1 treatment did not affect angiotensin II levels 
in Insr+/–D, Insr+/–N, and WT mice (data not shown). Thus, TAPI-1 
treatment reduced fed glucose, insulin, and TNF-α levels in Insr+/–D 
mice to levels observed in WT mice. This may reflect an increase 
in peripheral tissue insulin sensitivity secondary to TAPI-1–depen-
dent reduction of TACE activity. To address this possibility, we per-
formed insulin tolerance tests before and after TAPI-1 treatment. 
These tests confirmed decreased insulin sensitivity in Insr+/–D mice 
(Figure 8E). Administration of TAPI-1 for 1 week caused a sig-
nificant recovery of insulin sensitivity in Insr+/–D mice (Figure 8F). 
Interestingly, we found a positive effect of TAPI-1 treatment on 
insulin sensitivity in Insr+/–N mice (Figure 8F). We speculated that 
a reduction in Timp3 activity and the consequent systemic increase 
of TNF-α levels could explain the increase in MMPs in vascular cells 
observed in Insr+/–D mice. TNF-α plays a role in atherosclerosis, 
enhancing the local prothrombotic and proinflammatory states, 
which sustain plaque growth and instability. Enhanced expression 
of MMPs has been linked to multiple mechanisms germane to the 
progression of atherosclerosis lesions, such as SMC migration and 
lesion instability (27). Therefore, we measured MMP-2 and MMP-9 
in Insr+/–D mice before and at the end of 1 week of TAPI-1 adminis-
tration and 2 weeks after discontinuing TAPI-1. Both pro–MMP-2 
and pro–MMP-9 were found to be decreased by TAPI-1, with a ten-
dency to revert to initial levels after TAPI-1 withdrawal (Figure 8G). 
To elucidate whether blockage of TACE/MMP activity by TAPI-1 
administration is associated with decreased expression of proin-
flammatory mediators in Insr+/–D vasculature, we assessed indices 
Figure 4
Effect of Timp3 KD on glucose metabolism. 
Glucose (A) and insulin (B) levels during an 
intraperitoneal glucose tolerance test in WT mice 
(open squares), WT/Timp3KD (filled squares), 
Insr+/–N (filled circles), Insr+/–N/Timp3KD 
mice (open circles), and Insr+/–N/Veh (open 
diamonds) mice (n = 6 per group). Data are 
expressed as mean ± SD. **P < 0.01, †P < 0.001 
by 2-way ANOVA for Insr+/–N/Timp3KD com-
pared with other groups. 2-DOG uptake into 
triceps (C) and perigonadal WAT (D) during a 
glucose tolerance test. (E) Glucose uptake into 
liver, as estimated by 2-DOG incorporation into 
glycogen (n = 6 per group). Data in C–E repre-
sent moles/milligram protein per minute and are 
expressed as mean ± SD. *P < 0.05 compared 
with WT by 1-way ANOVA for Insr+/–N/Timp3KD 
compared with other groups.
research article
3500	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 115   Number 12   December 2005
of vascular inflammation. By Western blotting, a 2.8-fold decrease 
in MCP-1 antigen was observed in TAPI-1–treated Insr+/–D mice 
compared with pretreatment levels (Figure 8H). Two weeks after 
discontinuing TAPI-1, levels of MCP-1 increased to pretreatment 
Figure 5
Effect of Timp3 KD on insulin signaling in WT and Insr+/– mice. (A) TNF-α signaling in skeletal muscle measured by phosphorylation state of 
JNK-1/2 and of Ser307 in IRS1. After an overnight fast, 6-month-old WT, WT/Timp3KD, Insr+/– and Insr+/–/Timp3KD mice were injected with 
either saline (–) or 25 mU/kg of insulin (Ins). Skeletal muscle (B–E), livers (F–H), and WAT (I) were collected 5–10 minutes later. Protein extracts 
were prepared, immunoprecipitated with antibodies against Insr (B) and IRS-1 (C), and after gel separation were immunoblotted with antibod-
ies specific for phosphotyrosine (pyTyr) (PY20) and normalized by reblotting with specific antibodies. PI3K activity (D, F, and I) was measured 
in phosphotyrosine immunoprecipitates by ELISA assay. The levels of total AKT1/2 and activated AKT (p-Ser473) (E and G), total glycogen 
synthase kinase 3β (GSK3β) and inactivated GSK3β (p-Ser9) (H) were determined by immunoblotting of the original lysates. Band intensities 
were quantified by densitometry and expressed as mean ± SD (n = 3 mice per group). *P < 0.05, **P < 0.01, †P < 0.001 by 1-way ANOVA for 
Insr+/–N/Timp3KD compared with other groups.
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levels (Figure 8H). In Insr+/–D mice treated with TAPI-1, levels of 
VCAM-1 were reduced by 40% and increased to pretreatment levels 
after TAPI-1 was discontinued (Figure 8I). Inhibition of TACE by 
TAPI-1 decreased levels of cox-2 and LOX-1 antigens in the aortas 
of Insr+/–D mice by 40% and 238%, respectively (Figure 8, J and K).
Discussion
Epidemiological studies suggested that a tight control of risk fac-
tors may reduce chronic inflammation, so as to help the preven-
tion of cardiovascular events in patients affected by type 2 diabetes 
and lower the risk for type 2 diabetes in patients affected by car-
diovascular disease (28–30). Although clinical trials with angioten-
sin-converting enzyme inhibitors and salicylates suggest that the 
reduction of inflammation can help to maintain glucose homeo-
stasis (29, 30), the molecular mechanisms explaining how control 
of inflammation influences both type 2 diabetes and atherosclero-
sis are only partially known.
Here, we describe a novel concept in diabetes/atherosclerosis 
pathogenesis: interaction between defective insulin action and 
loss of control of TACE, a protease that regulates soluble TNF-α 
levels, may synergize to induce concurrently hyperglycemia and 
vascular inflammation. Increased activation of TACE is a con-
sequence of the reduced expression of its inhibitor Timp3. We 
demonstrated through in vivo assays that genetic interaction 
between systemic Insr haploinsufficiency and Timp3 deficiency 
in the skeletal muscle impairs glucose uptake, a sign of insulin 
resistance. The phenotype of mice carrying a reduced Timp3 
expression in muscle and vasculature combined with systemic 
Insr haploinsufficiency resembles that of muscle-specific, insulin-
resistant knockout–50% (MIRKO-50%) mice, in which only the 
combination of a specific muscle Insr deletion along with anoth-
er mild defect (a systemic Insr haploinsufficiency) causes hyper-
glycemia and hyperinsulinemia in aged animals (31). It was also 
suggested that a defect in adipose tissue and liver is necessary to 
cause overt diabetes (32). Remarkably, glucose uptake is impaired 
in liver and WAT of Insr+/–N/Timp3KD mice. Therefore, it is pos-
sible that as a consequence of the interaction between the Insr 
haploinsufficiency and Timp3 deficiency, glucose shunted from 
muscle is not adequately metabolized in fat and liver. A similar 
mechanism has been suggested for muscle-specific GLUT4-null 
mice (32). Therefore, our model supports the hypothesis that 
to determine diabetes, a strong defect in one of the peripheral 
target tissues, as the one induced by interaction of Insr+/– and 
Timp3 in the muscle, should be flanked by mild defects in the 
other organs, such as those caused by Insr haploinsufficiency 
alone. Studies with mice with a systemic chronic haploinsuffi-
ciency of both Insr and Timp3 reveal that young animals manifest 
mild defects in insulin sensitivity and glucose tolerance, while 
adult heterozygous mice develop marked hyperglycemia and 
hyperinsulinemia. A similar phenotype was observed in double 
heterozygous Insr+/–Irs1+/– mice (9).
Using Insr+/– diabetic mice, in which there is evidence of 
unchecked TACE activation, we tested the hypothesis that recov-
ery of Timp3 activity could be a valid approach to concurrently 
reducing diabetes and vascular inflammation. In fact, the blockage 
of TACE as well as MMP-2 and MMP-9 by a synthetic inhibitor 
markedly improves hyperglycemia, hyperinsulinemia, and markers 
of inflammation such as VCAM-1, LOX-1, MCP-1, and cox-2.
Since type 2 diabetes and atherosclerosis are multifacto-
rial diseases and many patients develop macrovascular disease 
before frank hyperglycemia occurs, it is plausible that common 
pathways play a role in the development of both the diseases 
(3–5). We suggest that Timp3, which is a powerful regulator 
of inflammation (14, 33), can also curtail failure in glucose 
Figure 6
Glucose homeostasis in Insr+/–Timp3+/–, Insr+/–Tace+/–, Insr+/–, Timp3+/–, Tace+/–, and WT littermates at 3 months. Fasted glucose (A), fasted 
insulin (B), fed glucose (C), and fed insulin (D) levels in mice (n = 8–10 per group). Data are expressed as mean ± SD. †P < 0.001 for Insr+/–
Timp3+/– versus Timp3+/–, Tace+/–, and WT mice by 1-way ANOVA; #P < 0.01 for Insr+/–Timp3+/– versus Insr+/– and Insr+/–Tace+/– mice; *P < 0.05 
for Insr+/–Timp3+/– versus all the other genotypes by 1-way ANOVA. (E) Glucose levels after intraperitoneal glucose load. Data are expressed 
as mean ± SD (n = 5 per group). *P < 0.05 for Insr+/–Timp3+/– versus other genotypes by 2-way ANOVA. (F) Insulin tolerance test (0.75 U kg–1). 
Data are expressed as mean ± SD (n = 5 per group). *P < 0.05 for Insr+/–/Timp3+/– versus other genotypes by 2-way ANOVA.
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metabolism sustained by genetic or secondary insulin resis-
tance. Since Timp3 is also an inhibitor of VEGF activity (34), 
Insr+/–Timp3+/– mice could be a useful model for studying the 
connection between insulin sensitivity, inflammation, and vas-
cular complications of diabetes.
Anti–TNF-α treatment in human diseases such as diabetes/
obesity and heart failure is biologically relevant, but the few 
attempts using monoclonal antibodies for chronic TNF-α neu-
tralization have been ineffective (35–38). Our study suggests 
that TNF-α neutralization might also be obtained through use 
of appropriate TACE inhibitors.
In conclusion, we provide a direct mechanistic relationship 
among insulin action, control of inflammation, and the patho-
physiology of atherosclerosis and diabetes. In the Insr+/–D mice, 
through recovery of Timp3 activity, it is possible to inhibit TACE 
and to break the synergistic effect of TNF-α and Insr haploinsuf-
ficiency on insulin sensitivity. Based on our findings, we propose 
that the TIMP3/TACE system is involved in the pathogenesis of 
atherosclerosis and type 2 diabetes in human subjects and as such 
may be exploited for therapeutic purposes.
Methods
Animal husbandry, genotyping, and analytical procedures. Insr+/– mice used 
for the differential display were previously described (8). Insr+/– mice on 
a C57BL/129SV mixed background were obtained from Columbia Uni-
versity; generation and genotyping of these mice has been described in 
previous publications (7–9). Timp3+/– and Tace+/– mice on a C57BL/129SV 
mixed background were previously described (14, 26). Bleeding and meta-
bolic testing procedures have been previously described (7–9). TNF-α 
levels were measured using a commercial ELISA kit (BD Biosciences 
— Pharmingen) in accordance with the manufacturer’s instructions (14). 
Animal studies were approved by the University of Rome “Tor Vergata” 
Animal Care and Use Committee.
mRNA display. To identify differentially expressed genes, we used the 
Hieroglyph differential display kit (Genomyx Corp.) according to the 
manufacturer’s instructions.
DNA sequencing. Following reamplification, PCR products were purified 
on NICK Columns (Amersham Biosciences) and subjected to sequence 
analysis using [33P]-labeled di-deoxynucleotide terminators in PCR 
sequencing with Thermo Sequenase DNA Polymerase (Amersham Biosci-
ences). Each PCR product was analyzed in 4 independent reactions. The 
Figure 7
Glucose homeostasis in Insr+/–Timp3+/–, Insr+/–Tace+/–, Insr+/–, Timp3+/–, Tace+/–, and WT littermates at 6 months. Fasted glucose (A), fasted insulin 
(B), fed glucose (C), and fed insulin (D) levels (n = 8–10 per group). Data are expressed mean ± SD. †P < 0.001 for Insr+/–/Timp3+/– versus other 
genotypes by 1-way ANOVA; **P < 0.01 for Insr+/–Timp3+/– versus Timp3+/–, Tace+/–, and WT; #P < 0.05, Insr+/–Timp3+/– versus Insr+/– and Insr+/–
Tace+/– by 1-way ANOVA. Glucose (E) and insulin (F) levels during an intraperitoneal glucose tolerance test. Data are expressed as mean ± SD 
(n = 5 per group). †P < 0.001, Insr+/–Timp3+/– versus other genotypes by 2-way ANOVA. (G) Insulin tolerance test (0.75 U kg–1). Data are 
expressed as mean ± SD (n = 5 per group). †P < 0.001, Insr+/–Timp3+/– versus Timp3+/–, Tace+/–, and WT; *P < 0.05, Insr+/–/Timp3+/– versus Insr+/– 
and Insr+/–Tace+/– by 2-way ANOVA at 10 and 30 minutes; and ‡P < 0.001, Insr+/–Timp3+/– versus Insr+/–Tace+/–, Insr+/–, Timp3+/–, Tace+/–, and WT 
by 2-way ANOVA at 60 minutes. (H) Quantification of TNF-α in Insr+/–Timp3+/–, Insr+/–Tace+/–, Insr+/–, Timp3+/–, Tace+/–, and WT littermates.
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products of the sequencing reactions were analyzed on denaturing 9M 
urea/6% polyacrylamide gels and detected by autoradiography.
Extraction of Timp3 for Western blots and reverse zymography. For the extraction 
of matrix-bound Timp3, tissues were treated as described by Woessner and 
Figure 8
Glucose homeostasis in Insr+/–D mice is improved by inhibition of Tace/MMP activity. (A) Fed glucose levels were measured before (Pre-Ab) and 
24 hours after (Post-Ab) anti–TNF-α antibody injection in Insr+/–D (n = 6). **P < 0.01 by 1-way ANOVA. (B) Fed glucose levels were measured 
before and on day 7 of TAPI-1 treatment and 14 days after discontinuing TAPI-1 in Insr+/–D, Insr+/–N, and WT mice at 6 months of age (n = 12 per 
group). †P < 0.001 by 1-way ANOVA. (C) Fed insulin levels before, on day 7 of TAPI-1 treatment, and day 14 after discontinuing TAPI-1 in Insr+/–D, 
Insr+/–N, and WT mice at 6 months of age (n = 12 per group). †P < 0.001 by 1-way ANOVA. (D) TNF-α levels before and after TAPI-1 treat-
ment (7 days) in Insr+/–D mice. *P < 0.05. (E and F) Insulin tolerance test (0.75 U kg–1) in Insr+/–D (open circles), Insr+/–N (filled circles), and WT 
(filled squares) mice at 6 months of age (n = 6 per group) before and at the end of TAPI-1 treatment. *P < 0.05, **P < 0.01, †P < 0.001 by 2-way 
ANOVA. (G) MMP-9 and MMP-2 measured by zymography (n = 3 per group). Mouse MMP-9 and human MMP-2/9 were used as standards. 
MCP-1 (H), VCAM-1 (I), cox-2 (J), and LOX-1 (K) by Western blotting. Gel loading was normalized by tubulin. Data from 3 separate experiments 
are summarized in the bar graphs and expressed as mean ± SD. *P < 0.05, **P < 0.01 by 1-way ANOVA.
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coworkers (39). Briefly, hind limb skeletal muscles and aortas were removed, 
washed 3 times with cold 50 mM Tris, pH 7.5, 0.03% sodium azide, snap 
frozen, pulverized, and homogenized in 500 µl of the same buffer contain-
ing 0.1% Triton X-100 for 6 minutes at 4°C. The mixture was centrifuged 
at 13,500 g for 20 minutes. The pellet was washed 2 times and resuspended 
in the same volume of cold 50 mM Tris, pH 7.5, 0.03% sodium azide, 50 µM 
Z-Phe-chloromethyl ketone, 50 µM aminoethyl-benzenesulfonyl fluoride. 
Extractants (a mixture of chondroitin sulfates A, B, and C; Sigma-Aldrich) 
were added to a final concentration of 0.2 mg/ml. Extraction at 4°C for 30 
minutes was followed by centrifugation at 17,000 g for 10 minutes.
Analysis of TACE substrates shedding in total muscle homogenates and purified skel-
etal muscle membranes. TACE activity was measured by adding 10 µM of Abz-
LAQAVRSSSR-Dpa to equal amounts (100 µg) of hind limb skeletal muscle 
lysates resuspended in TACE buffer for 1 hour (50 mM Tris-Cl, pH 7.4, 25 mM 
NaCl, and 4% glycerol, room temperature). Fluorescence was monitored at 
λex 320 nm and λem 420 nm over a period of 10 minutes (40). We purchased 
recombinant Timp3 and TIMP1 from Oncogene Science and R&D Systems, 
respectively. BMS-275291 was a gift of John Bird (Celltech Group, Cam-
bridge, United Kingdom). Shedding of TACE substrates was measured on 
skeletal muscle membranes using specific antibodies (all from Santa Cruz 
Biotechnology Inc.) following methods described by Xu et al. (25).
Muscle and aortas lysates for Western blots. Skeletal muscle lysates were 
obtained as described previously (9). Fresh aortas were collected separately, 
pulverized under liquid nitrogen, and extracted with the use of ice-cold lysis 
buffer (10 mmol/l sodium phosphate, pH 7.2, containing 150 mmol/l NaCl 
[PBS], and 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, and 0.2% 
sodium azide) for 1 hour at 4°C. Insoluble material was removed by centrifu-
gation at 13,800 g at 4°C for 10 minutes. Supernatant (100 µg) was added to 
Laemmli buffer and heated in boiling water for 4 minutes. Equal amounts 
from 3 animals for each genotype were subjected to immunoblot analysis.
Western blots. Total lysates, ECM extracts, or membrane lysates prepared 
as described above were subjected to SDS-PAGE and immunoblot analy-
sis as described. The following antibodies were used: anti–mouse Timp-3 
(Santa Cruz Biotechnology Inc.), anti–MCP-1, anti–VCAM-1, anti–cox-2, 
anti–LOX-1 (Santa Cruz Biotechnology Inc.), anti–TNF-α antibody (Endo-
gen; Pierce Biotechonology Inc.); anti–phospho-Ser307 IRS-1 (Cell Signal-
ing Technology Inc.). Specific anti-mouse α-tubulin antibody (Sigma-
Aldrich) and total protein content (14) were measured as loading control.
SDS-PAGE zymography and reverse zymography. Aorta lysates, obtained from 
aortic root of Insr+/–D, Insr+/–N, and WT mice, were subjected to zymography 
and reverse zymography experiments as described previously (41). Briefly, 
equal amounts of tissue extract protein (20 µg) were mixed with an equal 
volume of 2× non-reducing sample buffer. Twenty-microliter aliquots were 
electrophoresed in the presence of SDS in discontinuous 10% SDS-poly-
acrylamide gels containing gelatin or casein (NOVEX; Invitrogen Corp.). 
After running, gels were incubated in NOVEX Zymogram Renaturing Buffer 
(room temperature for 30 minutes), equilibrated in the NOVEX Zymogram 
Developing Buffer (room temperature for 30 minutes), and subsequently 
incubated in the same buffer for 18 hours at 37°C. Then gels were stained 
with Coomassie blue R-250 (room temperature for 30 minutes), followed 
by destaining in 5% methanol and 7% acetic acid. In some experiments, to 
verify the metalloproteinase activity detected by zymography, identical gels 
were incubated in the above-mentioned buffer containing either 20 mmol/l 
EDTA, an inhibitor of MMPs, or 1 mmol/l PMSF, an inhibitor of serine 
proteases. Zymography gels were then stained and destained as described 
above. To identify gelatinases, we used both purified human MMP-2 and 
MMP-9 (a generous gift from Dylan Edwards, University of East Anglia, Nor-
wich, United Kingdom) and mouse MMP-9 (Sigma-Aldrich). Reverse zymog-
raphy was performed to measure TIMP activities as follows: samples were 
electrophoresed in discontinuous 12% SDS-PAGE gels containing 1 mg/ml 
gelatin and conditioned medium from baby hamster kidney cells expressing 
gelatinase A (a generous gift from Dylan Edwards). The gels were washed and 
incubated for 24 hours at 37°C in regenerating buffer (50 mmol/l Tris-HCl, 
pH7.5, and 5 mmol/l CaCl2). Under these conditions, TIMPs inhibit gelatin 
digestion by activated MMPs, producing dark blue bands against a lighter 
background. Purified human Timp3 (Calbiochem) was used as control. 
Density of bands was quantified by the NIH IMAGE program, version 1.6 
(http://rsb.info.nih.gov/nih-image/).
RNA extraction and real-time quantitative PCR analysis. Total cellular RNA 
isolation and real-time PCR experiments were performed as described pre-
viously (42). Total RNA was isolated from fresh mouse aortas and hind 
limb muscles using TRIzol reagents (Invitrogen Corp.). Real-time PCR was 
carried out on individual samples from adult mice using a Roche Light-
Cycler PCR instrument and LightCycler RT-PCR kit (Roche Diagnostics 
Corp.). Each reaction was carried out in triplicate using standard reaction 
conditions. The following primers were employed: Timp3, forward 5′-ACC-
GACATGCTCTCCAA-3′ and reverse, 5′-CCTCTGACATGCACAC-3′.
Design of siRNAs and intramuscular injection. We used the target finder 
and design tool (GenScript Corp.) to identify target siRNAs. Five siRNA 
sequences (inserts 1–5) were identified and inserted in pRNA-U6.1/neo 
expression vector. The siRNA sequences were TCCTGCTACTACTT-
GCCTTGT (insert 1), GCAAGATGTACACAGGACTGT (insert 2), GCCT-
CAAGCTAGAAGTCAACA (insert 3), CAATTGCAAGATCAAGTCCTG 
(insert 4), and TGAAGATGTACCGAGGCTTCA (insert 5). Transfection of 
3T3L1 cells was performed with siPORT reagents (Ambion Inc.) according 
to the manufacturer’s instructions. For in vivo delivery, 50 µl of a solution 
(Mirus Bio Corp.) (43) containing 50 µg of the plasmid encoding timp3 
siRNA (Timp3KD) or the plasmid alone (Veh) were injected intramuscu-
larly. timp3 expression was measured by real-time RT-PCR and Western 
blotting. Glucose levels were measured daily for 72 hours.
In vivo tissue glucose transport during a glucose tolerance test. 2-Deoxy-d-[1, 2-
3H]-glucose (Amersham Biosciences) was mixed with 20% dextrose before 
intraperitoneal injection (2 g/kg body weight; 10 µCi/mouse) into weight-
matched 6-month-old male mice (WT, WT/Timp3KD, Insr+/–, Insr+/–N/Timp-
3KD, and Veh-Insr+/– mice; n = 5 for each group). Blood samples were obtained 
from tail veins at 0, 15, 30, 45, 60, and 120 minutes and used to determine glu-
cose-specific activity as described previously (23). At 120 minutes, mice were 
killed and tissues were snap-frozen in liquid nitrogen. To determine tissue accu-
mulation of 2-deoxyglucose-6-phosphate (2-DOG-6-phosphate), 100–500 mg 
tissue (triceps and perigonadal adipose tissue) was homogenized and processed 
as described previously (23). To calculate the 2-DOG uptake, the counts (degen-
erations per minute) were divided by the integrated glucose-specific activity area 
under the curve and normalized to the sample protein content.
2-DOG incorporation into liver glycogen and liver glycogen measurement during 
a glucose tolerance test. Frozen liver (50–75 mg) was pulverized with mortar 
and pestle in liquid nitrogen and digested. Macromolecules were then 
allowed to precipitate and used to determine radioactivity incorporation 
as described previously (23). To determine 2-DOG incorporation into liver 
glycogen, [3H]radioactivity in glycogen counts (degenerations per minute) 
was divided by the integrated glucose-specific activity area under the curve 
and corrected for sample protein content.
Insulin signaling studies. Insulin signaling studies with phosphotyrosine or 
phosphospecific antibodies were performed and PI3K activity was assessed 
as previously described (9–11, 43).
TAPI and anti–TNF-α antibody treatment. Anti–TNF-α neutralizing 
antibody (CALTAG Laboratories) was administered by intraperitoneal 
injections at 10 mg/kg/body weight/d to 6 month-old mice, and glu-
cose levels were measured 24 hours after the injection. TAPI-1 (N-(R)-[2- 
(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-l-naphthyl-alanyl-
l-alanine,2-aminoethyl amide) (Peptides International Inc.) was admin-
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istered by intraperitoneal injections at 10 mg/kg/body weight/d to 
6-month-old mice for 7 days consecutively. Glucose levels were measured 
daily during the treatment. Insulin tolerance tests were performed at day 
0 and at day 8. Mice were killed at day 0, day 8 of treatment, and 14 days 
after discontinuing TAPI-1.
Statistics. Results of the experimental studies are expressed as mean ± SEM 
or mean ± SD, as indicated. Statistical analysis were performed using the 
ANOVA or unpaired Student’s t test as indicated. Values of P < 0.05 were 
considered statistically significant.
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